In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.
The in vitro activity of LY303366, a new echinocandin derivative, was evaluated with 191 yeast isolates by a broth microdilution method. The MICs at which 50% of the isolates were inhibited were 0.125 microg/ml for Candida albicans and C. tropicalis, 0.25 microg/ml for C. krusei, C. kefyr, and C. glabrata, and 2.0 microg/ml for C. parapsilosis.
Uzun
O
O
Department of Medicine, Hacettepe University School of Medicine, Ankara, Turkey. ou01-k@servis2.net.tr
Kocagöz
S
S
Cetinkaya
Y
Y
Arikan
S
S
Unal
S
S
D000666:Amphotericin B / Q000494:pharmacology*; D000077612:Anidulafungin; D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification; D054714:Echinocandins; D015725:Fluconazole / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D010456:Peptides, Cyclic / Q000494:pharmacology*
D000935:Antifungal Agents; D054714:Echinocandins; D010456:Peptides, Cyclic; D000666:Amphotericin B; D015725:Fluconazole; D000077612:Anidulafungin